BOULDER, Colo. & SAN DIEGO--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) and VentiRx Pharmaceuticals Inc., a privately held biopharmaceutical company, announced today that the two companies have entered into a license agreement granting VentiRx exclusive worldwide rights to Array’s Toll-like receptor (TLR) program. The program contains a number of development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy.
